Omega-3 fatty Acids in cardiovascular disease - An uphill battle

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 92, Issue , 2015, Pages 41-47

  Von Schacky, Clemens ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Omegametrix GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; CARDIOTONIC AGENT;

ARTICLE; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL LEVEL; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIET SUPPLEMENTATION; ERYTHROCYTE; FAT INTAKE; FATTY ACID BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION; SUDDEN CARDIAC DEATH; ANIMAL; CARDIOVASCULAR DISEASES; LIPID METABOLISM; METABOLISM; MORTALITY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; FATTY ACIDS, OMEGA-3; HUMANS; LIPID METABOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84921433754     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.05.004     Document Type: Article

References (113)

1. von Schacky C. Omega-3 fatty acids: anti-arrhythmic, pro-arrhythmic, or both?. Front. Cardiac Electrophysiol. 2012, 3:98.
2. Galan P., Kesse-Guyot E., Czernichow S., Briancon S., Blacher J., Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Br. Med. J. 2010, 341:c6273. SU.FOL.OM3 Collaborative Group.
3. Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke H., OMEGA Study Group, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
4. Einvik G., Klemsdal T.O., Sandvik L., Hjerkinn.E.M. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur. J. Cardiovasc. Prev. Rehabil. 2010, 17:588-592.
5. Kromhout D., Giltay E.J., Geleijnse J.M. n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010, 363:2015-2026. Alpha Omega Trial Group.
6. Bosch J., Gerstein H.C., Dagenais G.R., Díaz R R., Dyal L., Jung H., et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 2011, 367:319-328. ORIGIN Trial Investigators.
7. Roncaglioni M.C., Tombesi M., Avanzini F., Barlera S., Caimi V., Longoni P., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 2013, 368:1800-1808. Risk and Prevention Study Collaborative Group, (Erratum in N. Engl. J. Med. 368 (2013) 2146).
8. Chowdhury R., Stevens S., Gorman D., Pan A., Warnakula S S., Chowdhury S., et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. Br. Med. J. 2012, 345:e6698.
9. Kotwal S., Jun M., Sullivan D., Perkovic V., Neal B. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ. Cardiovasc. Qual. Outcomes 2012, 5:808-818.
10. Rizos E.C., Ntzani E.E., Bika E., Kostapanos M.S., Elisaf M.S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. J. Am. Med. Assoc. 2012, 308:1024-1033.
11. Kwak S.M., Myung S.K., Lee Y.J., Seo H.G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch. Intern. Med. 2012, 172:686-694. Korean Meta-analysis Study Group.
12. Delgado-Lista J., Perez-Martinez P., Lopez-Miranda J., Perez-Jimenez.F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br. J. Nutr. 2012, 107(Suppl. 2):S201-S213.
13. Hu F.B., Bronner L., Willett W.C., Stampfer M.J., Rexrode K.M., Albert C.M., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. J. Am. Med. Assoc. 2002, 287:1815-1821.
14. Mozaffarian D., Rimm.E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. J. Am. Med. Assoc. 2006, 296:1885-1899.
15. Harris W.S., Poston W.C., Haddock C.K. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007, 193:1-10.
16. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG), et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Fifth Joint Task Force of the European Society of Cardiology; European Association of Echocardiography; European Association of Percutaneous Cardiovascular Interventions; European Heart Rhythm Association; Heart Failure Association; European Association for Cardiovascular Prevention & Rehabilitation; European Atherosclerosis Society; International Society of Behavioural Medicine; European Stroke Organisation; European Society of Hypertension; European Association for the Study of Diabetes; European Society of General Practice/Family Medicine; International Diabetes Federation Europe; European Heart Network. Eur. J. Prev. Cardiol. 2012, 19:585-667.
17. S.C. Smith Jr., E.J. Benjamin, R.O. Bonow, L.T. Braun, M.A. Creager, B.A. Franklin BA, et al.; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 124 (2011) 2458-2473.
18. Brouwer I.A., Raitt M.H., Dullemeijer C., Kraemer DF D.F., Zock P.L., Morris C., et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur. Heart J. 2009, 30:820-826.
19. Mozaffarian D., Wu J.H., de Oliveira Otto M.C., Sandesara C.M., Metcalf R.G., Latini R., et al. Fish oil and post-operative atrial fibrillation: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 2013, 61:2194-2196.
20. Siscovick D.S., Raghunathan T.E., King I., Weinmann S., Wicklund K.G., Albright J., et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the riskof primary cardiac arrest. J. Am. Med. Assoc. 1995, 275:836-837.
21. Albert C.M., Campos H., Stampfer M.J., Ridker P.M., Manson J.E., Willett W.C., Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 2002, 346:1113-1118.
22. Gronroos N.N., Alonso.A. Diet and risk of atrial fibrillation - epidemiologic and clinical evidence. Circ. J. 2010, 74:2029-2038.
23. Wu J.H., Lemaitre R.N., King I.B., Song X., Sacks F.M., Rimm E.B. Association of plasma phospholipid long-chain omega-3 Fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation 2012, 125:1084-1093.
24. D.P. Zipes, A.J. Camm, M. Borggrefe, A.E. Buxton, B. Chaitman, M. Fromer, American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Societyet al.; ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 114 (2006) e385-e484.
25. Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012, 33:2719-2747.
26. Wann L.S., Curtis A.B., January C.T., Ellenbogen K.A., Lowe JE J.E., Estes N.A., ACCF/AHA Task Force Members, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:104-123.
27. Investigators Gissi-H.F., Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
28. Mozaffarian D., Lemaitre R.N., King I.B., Song X., Spiegelman D., Sacks F.M., et al. Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann. Intern. Med. 2011, 155:160-170.
29. Masson S., Marchioli R., Mozaffarian D., Bernasconi R., Milani V., Dragani L., et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. Am. Heart J. 2013, 165:208-215.
30. Jessup M., Abraham W.T., Casey D.E., Feldman A.M., Francis G.S., T.G., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
31. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., ESC Committee for Practice Guidelines, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012, 33:1787-1847.
32. Harris W.S., von Schacky C., Park Y. Standardizing methods for assessing omega-3 fatty acid biostatus. The Omega-3 Fatty Acid Deficiency Syndrome 2013, Nova Science Publishers, Hauppauge, NY, USA, (chapter XIX). R.K. McNamara (Ed.).
33. Hlatky M.A., Greenland P., Arnett D.K., Ballantyne C.M., Criqui M.H., Elkind M.S., et al. American Heart Association Expert Panel on subclinical atherosclerotic diseases and emerging risk factors and the stroke council. Circulation 2009, 119:2408-2416.
34. Helfand M., Buckley D.I., Freeman M., Fu R., Rogers K., Fleming C., Humphrey L.L. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2009, 151:496-507.
35. Harris W.S., von Schacky C. The Omega-3 Index: a new risk factor for death from CHD?. Prev. Med. 2004, 39:212-220.
36. Pottala J.V., Espeland M.A., Polreis J., Robinson J., Harris W.S. Correcting the effects of -20°C storage and aliquot size on erythrocyte fatty acid content in the women's health initiative. Lipids 2012, 47:835-846.
37. von Schacky C., Fischer S., Weber P.C. Long term effects of dietary marine II-3 fatty acids upon plasma- and cellular lipids, platelet function and eicosanoid formation in humans. J. Clin. Invest. 1985, 76:1626-1631.
38. Harris W.S., Thomas R.M. Biological variability of blood omega-3 biomarkers. Clin. Biochem. 2010, 43:338-340.
39. Shearer G.C., Chen J., Chen Y., Harris W.S. Myocardial infarction does not affect fatty acid profiles in rats. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81:411-416.
40. Harris W.S., Varvel S.A., Pottala J.V., Warnick G.R., McConnell.J.P. The comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: implications for clinical utility. J. Clin. Lipidol. 2014, (in press).
41. Harris W.S., Pottala J.V., Vasan R.S., Larson M.G., Robins S.J. Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in Older Americans. J. Nutr. 2012, 142:1297-1303.
42. Harris W.S., Sands S.A., Windsor S.L., Ali H.A., Stevens T.L., Magalski A., et al. Omega-3 fatty acid levels in transplanted human hearts: effect of supplementation and comparison with erythrocytes. Circulation 2004, 110:1645-1649.
43. Arnold C., Markovic M., Blossey K., Wallukat G., Fischer R., Dechend R., et al. Arachidonic acid-metabolizing cytochrome P-450 enzymes are targets of omega-3 fatty acids. J. Biol. Chem. 2010, 285:32720-32733.
44. von Schacky C. The Omega-3 Index as a risk factor for cardiovascular diseases. Prostaglandins Other Lipid Mediators 2011, 96:94-98.
45. Ebbesson S.O., Devereux R.B., Cole S., Ebbesson L.O., Fabsitz R.R., Haack K., et al. Heart rate is associated with red blood cell fatty acid concentration: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Am. Heart J. 2010, 159:1020-1025.
46. Sala-Vila A., Harris W.S., Cofán M., Pérez-Heras A.M., Pintó X., Lamuela-Raventós R.M., et al. Determinants of the omega-3 index in a Mediterranean population at increased risk for CHD. Br. J. Nutr. 2011, 106:425-431.
47. Harris W.S., Pottala J.V., Lacey S.M., Vasan R.S., Larson M.G., Robins S.J. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis 2012, 225:425-431.
48. Köhler A., Bittner D., Löw A., von Schacky C. Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index. Br. J. Nutr. 2010, 104:729-736.
49. Aarsetoey H., Pönitz V., Nilsen O.B., Grundt H., Harris W.S., Nilsen D.W. Low levels of cellular omega-3 increases the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation 2008, 78:258-264.
50. Aarsetøy H., Aarsetøy R., Lindner T., Staines H., Harris W.S., Nilsen.D.W.T. Low levels of the Omega-3 Index are associated with sudden cardiac arrest and remain stable in survivors in the subacute phase. Lipids 2011, 46:151-161.
51. Pottala J.V., Garg S., Cohen B.E., Whooley M.A., Harris WS W.S. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the heart and soul study. Circ. Cardiovasc. Qual. Outcomes 2010, 3:406-412.
52. Harris W.S., Kennedy K.F., O'Keefe J.H., Spertus J.A. Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction. Int. J. Cardiol. 2013, 168:53-59.
53. M. Abuannadi, J.H. O'Keefe, J.A. Spertus, K.F. Kennedy, W.S. Harris,et al., Omega-3 Index: an independent predictor of 1 year all cause mortality in myocardial infarction (MI) patients, in: Poster 174, AHA QCOR Meeting, May 19-21, 2010 (accessed 13.03.13). http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_319392.pdf.
54. Aarsetoey H., Pönitz V., Grundt H., Staines H., Harris WS W.S., Nilsen D.W. (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome. J. Nutr. 2009, 139:507-513.
55. Harris W.S., Reid K.J., Sands S.A., Spertus J.A. Blood omega-3 and trans fatty Acids in middle-aged acute coronary syndrome patients. Am. J. Cardiol. 2007, 99:154-158.
56. Block R.C., Harris W.S., Reid K.J., Sands S.A., Spertus J.A. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 2008, 197:821-828.
57. Park Y., Lim J., Lee J., Kim S.G. Erythrocyte fatty acid profiles can predict acute non-fatal myocardial infarction. Br. J. Nutr. 2009, 102:1355-1356.
58. Kim Y.J., Jeong D.W., Lee J.G., Lee H.C., Lee S.Y., Kim Y.J., et al. Omega-3 index and smoking in patients with acute ST-elevation myocardial infarction taking statins: a case-control study in Korea. Lipids Health Dis. 2012, 11:43.
59. Djoussé L., Akinkuolie A.O., Wu J.H., Ding E.L., Gaziano J.M. Fish consumption, omega-3 fatty acids and risk of heart failure: a meta-analysis. Clin. Nutr. 2012, 31:846-853.
60. Wilk J.B., Tsai M.Y., Hanson N.Q., Gaziano J.M., Djoussé L. Plasma and dietary omega-3 fatty acids, fish intake, and heart failure risk in the Physicians' Health Study. Am. J. Clin. Nutr. 2012, 96:882-888.
61. Shearer G.C., Pottala J.V., Spertus J.A., Harris W.S. Red blood cell fatty acid patterns and acute coronary syndrome. PloS One 2009, 4:e5444. 10.1371/journal.pone.0005444.
62. Park Y., Park S., Yi H., Kim H.Y., Kang S.J., Kim J., Ahn H. Low level of n-3 polyunsaturated fatty acids in erythrocytes is a risk factor for both acute ischemic and hemorrhagic stroke in Koreans. Nutr. Res. 2009, 29:825-830.
63. Duda M.K., O'Shea K.M., Tintinu A., Xu W., Khairallah R.J., Barrows B.R., et al. Fish oil but not flaxseed oil decreases inflammation and prevents pressure-overload induced cardiac dysfunction. Cardiovasc. Res. 2009, 81:319-327.
64. Billman G.E., Nishijima Y., Belevych A.E., Terentyev D., Xu Y., Haizlip K.M., et al. Effects of dietary omega-3 fatty acids on ventricular function in dogs with healed myocardial infarctions: in vivo and in vitro studies. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1219-H1228.
65. Yang R., Harris W.S., Vernon K., Thomas A.M., Qureshi N., Morrison D.C., van Way C.W. Pre-feeding with omega-3 fatty acids suppresses inflammation following hemorrhagic shock. J. Parenter. Enter. Nutr. 2010, 34:496-502.
66. Chen J., Shearer G.C., Chen Q., Healy C.L., Beyer A.J., Nareddy V.B., et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cGMP/PKG ehaviour in cardiac fibroblasts. Circulation 2011, 123:584-593.
67. Billman G.E., Harris WS W.S. Effect of dietary omega-3 fatty acids on the heart rate and the heart rate variability response to myocardial ischemia or submaximal exercise. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H2288-H2299.
68. Billman G.E., Carnes C.A., Adamson P.B., Vanoli E., Schwartz P.J. Dietary omega-3 fatty acids and susceptibility to ventricular fibrillation: lack of protection and a proarrhythmic effect. Circ. Arrhythm. Electrophysiol. 2012, 5:553-560.
69. Park Y., Moon H.M., Kim S.H. N-3 polyunsaturated fatty acid consumption produces neurobiological effects associated with prevention of depression in rats after the forced swimming test. J. Nutr. Biochem. 2012, 23:924-928.
70. Harris W.S., Gonzales M., Laney N., Sastre A., Borkon A.M. Effects of omega-3 fatty acids on heart rate in cardiac transplant recipients. Am. J. Cardiol. 2006, 98:1393-1395.
71. Harris W.S., Pottala J.V., Sands S.A., Jones P.G. Comparison of the effects of fish and fish oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. Am. J. Clin. Nutr. 2007, 86:1621-1625.
72. Larson M.K., Ashmore J.H., Harris K.A., Vogelaar J.L., Pottala JV J.V., Sprehe M., Harris W.S. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb. Haemost. 2008, 100:634-641.
73. Harris W.S., Lemke S.L., Hansen S.N., Goldstein D.A., DiRienzo M.A., Su A., et al. Stearidonic acid-enriched soybean oil increased the Omega-3 Index, an emerging cardiovascular risk marker. Lipids 2008, 43:805-811.
74. Carney R.M., Freedland K.E., Stein P.K., Steinmeyer B.C., Harris W.S., Rubin E.H., et al. Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease. Psychosom. Med. 2010, 72:748-754.
75. Lemke S.L., Vicini J.L., Su H., Goldstein D.A., Nemeth M.A., Krul E.S., Harris W.S. Dietary intake of stearidonic acid-enriched soybean oil increases the omega-3 index: randomized, double-blind clinical study of efficacy and safety. Am. J. Clin. Nutr. 2010, 92:766-775.
76. Neubronner J., Schuchardt J.P., Kressel G., Merkel M., von Schacky C., Hahn A. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur. J. Clin. Nutr. 2011, 65:247-254.
77. Skulas-Ray A.C., Kris-Etherton P.M., Harris W.S., vanden Heuvel J.P., Wagner P.R., West S.G. Dose response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy people with moderate hypertriglyceridemia. Am. J. Clin. Nutr. 2011, 93:243-252.
78. Park Y., Kim.M. Serum 25-hydroxyvitamin D concentrations are associated with erythrocyte levels of n-3 PUFA but not risk of CVD. Br. J. Nutr. 2011, 106:1529-1534.
79. Schuchardt J.P., Neubronner J., Kressel G., Merkel A., von Schacky C., Hahn A. Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: results from a six month randomized controlled trial. Prostaglandins Leukot. Essent. Fatty Acids 2011, 85:381-386.
80. Maki K.C., Bays H.E., Dicklin M.R., Johnson S.L., Shabbout M M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J. Clin. Lipidol. 2011, 5:483-492.
81. Dewell A., Marvasti F.F., Harris W.S., Tsao P., Gardner.C.D. Dose-dependent effects of plant and marine omega-3 fatty acids on inflammatory markers in insulin resistant adults. A randomized controlled trial. J. Nutr. 2011, 141:2166-2171.
82. Krul E.S., Lemke S.L., Mukherjea R., Taylor M.L., Goldstein DA D.A., Su H., et al. Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content. Prostaglandins Leukot. Essent. Fatty Acids 2012, 86:51-59.
83. An W.S., Lee S.M., Son Y.K., Kim S.E., Kim K.H., Han J.Y., et al. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot. Essent. Fatty Acids. 2012, 86:29-34.
84. Block R.C., Dier U., Calderonartero P., Shearer G.C., Kakinami L L., Larson M.K., et al. The effects of EPA+DHA and aspirin on inflammatory cytokines and angiogenesis factors. World J. Cardiovasc. Dis. 2012, 2:14-19.
85. Schmidt S., Stahl F., Mutz K.O., Scheper T., Hahn A., Schuchardt J.P. Transcriptome-based identification of antioxidative gene expression after fish oil supplementation in normo- and dyslipidemic men. Nutr. Metab. 2012, 9(1):45.
86. Skulas-Ray A.C., Kris-Etherton P.M., Harris W.S., West S.G. Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study. Ann. Behav. Med. 2012, 44:301-308.
87. An W.S., Lee S.M., Son Y.K., Kim S.E., Kim K.H., Han J.Y., et al. Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutr. Res. 2012, 32:495-502.
88. Schmidt S., Stahl F., Mutz K.O., Scheper T., Hahn A., Schuchardt J.P. Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial. Lipids Health Dis. 2012, 11:105.
89. Schuchardt J.P., Schmidt S., Kressel G., Dong H., Willenberg I., Hammock B.D., et al. Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men. Prostaglandins Leukot. Essent. Fatty Acids. 2013, 89:19-29.
90. Metkus T., Timpone J., Leaf D., Bidwell Goetz M., Harris W.S., Brown T. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients. HIV Med. 2013, 14:530-539.
91. von Schacky C., Angerer P., Kothny W., Theisen K., Mudra.H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1999, 130:554-562.
92. Schuchardt J.P., Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 2013, 89:1-8.
93. Dyerberg J., Madsen P., Møller J.M., Aardestrup I., Schmidt E.B. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot. Essent. Fatty Acids. 2010, 83:137-141.
94. Ulven S.M., Kirkhus B., Lamglait A., Basu S., Elind E., Haider T., et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids 2011, 46:37-46.
95. Davidson M.H., Johnson J., Rooney M.W., Kyle M.L., Kling.D.F. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. J. Clin. Lipidol. 2012, 6:573-584.
96. Hussey E.K., Portelli S., Fossler M.J., Gao F., Harris W.S., Blum R.A. Relative bioavailability of an emulsion formulation for omega-3-acid ethyl esters compared to thecommercially available formulation: a randomized, parallel-group, single-dose study followed by repeat dosing in healthy volunteers. Clin. Pharm. Drug Develop. 2012, 1:14-23.
97. Haug I.J., Sagmo L.B., Zeiss D., Olsen I.C., Draget K.I., Sternes T. Bioavailability of EPA and DHA delivered by gelled emulsions and soft gel capsules. Eur. J. Lipid Sci. Technol. 2011, 113:137-145.
98. Salisbury A.C., Harris W.S., Amin A.P., Reid K.J., O'Keefe J.H., Spertus J.A. Relation between red blood cell omega-3 fatty acid index and bleeding during acute myocardial infarction. Am. J. Cardiol. 2012, 109:13-18.
99. Larsson S.C., Kumlin M., Ingelman-Sundberg M., Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am. J. Clin. Nutr. 2004, 79:935-945.
100. Shannon J., King I.B., Moshofsky R., Lampe J.W., Gao D.L., Ray R.M., Thomas D.B. Erythrocyte fatty acids and breast cancer risk: a case-control study in Shanghai, China. Am. J. Clin. Nutr. 2007, 85:1090-1097.
101. Kuriki K., Hirose K., Wakai K., Matsuo K., Ito H., Suzuki T., et al. Breast cancer risk and erythrocyte compositions of n-3 highly unsaturated fatty acids in Japanese. Int. J. Cancer 2007, 121:377-385.
102. Norrish A.E., Skeaff C.M., Arribas G.L., Sharpe S.J., Jackson R.T. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br. J. Cancer 1999, 81:1238-1242.
103. Godley P.A., Campbell M.K., Gallagher P., Martinson F.E., Mohler J.L., Sandler R.S. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol. Biomarkers Prev. 1996, 5:889-895.
104. Ritch C.R., Wan R.L., Stephens L.B., Taxy J.B., Huo D., Gong E.M., et al. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J. Urol. 2007, 177:97-101.
105. Shannon J., O'Malley J., Mori M., Garzotto M., Palma A.J., King I.B. Erythrocyte fatty acids and prostate cancer risk: a comparison of methods. Prostaglandins Leukot. Essent. Fatty Acids. 2010, 83:161-169.
106. Newcomer L.M., King I.B., Wicklund K.G., Stanford.J.L. The association of fatty acids with prostate cancer risk. Prostate 2001, 47:262-268.
107. Okuno M., Hamazaki K., Ogura T., Kitade H., Matsuura T T., Yoshida R., et al. Abnormalities in fatty acids in plasma, erythrocytes and adipose tissue in Japanese patients with colorectal cancer. In Vivo 2013, 27:203-210.
108. Bloch M.H., Qawasmi.A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry 2011, 50:991-1000.
109. Montgomery P., Burton J.R., Sewell RP R.P., Spreckelsen T.F., Richardson A.J. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and ehaviour: a cross-sectional analysis from the DOLAB study. PloS One 2013, 24(8):e66697.
110. Sublette M.E., Ellis S.P., Geant A.L., Mann J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J. Clin. Psychiatry 2011, 72:1577-1584.
111. Bloch M.H., Hannestad.J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol. Psychiatry1. 2012, 17:1272-1282.
112. Stonehouse W., Conlon C.A., Podd J., Hill S.R., Minihane A.M., Haskell C., Kennedy.D. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am. J. Clin. Nutr. 2013, 97:1134-1143.
113. Witte A.V., Kerti L., Hermannstädter H.M., Fiebach J.B., Schreiber S.J., Schuchardt J.P., et al. Long-Chain Omega-3 Fatty Acids Improve Brain Function and Structure in Older Adults. Cereb. Cortex. 2013, (Epub ahead of print).